9 results
P
lung disease, li, ipf
I/C
baicalin, no intervention
O
reduced inflammation, decreased apoptosis, protected against progression
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
Li QL, Yao MF, Cao RY, Zhao K, Wang XD
I/C
short dental implants, splinted and nonsplinted prostheses
O
survival rates
P
E2F4, FOXM1, TFDP1, E2F1, SIN3A, JUN, DDX4, FOSL1, NOC2L, HMGA1, CDK1, CCNB1, AURKA, CDC20, CCNA2, SCNN1A, CDCA3, SOX6
I/C
O
survival prognosis, immune infiltrations, diagnostic efficacy
P
Individuals participating in blood flow restriction (BFR) training
I/C
BFR training, High-intensity resistance training (HIRT)
O
Muscular strength, hypertrophy, and endurance
P
red yeast rice preparations
I/C
RYR preparations, control treatments
O
adverse health outcomes
P
Orthodontic-surgical treatment patients
I/C
Conventional combined orthodontic-surgical treatment, No treatment or alternative treatments
O
Oral health-related quality of life
P
Dr. Heinrich, colleagues
I/C
systematic review and meta-analysis, the literature screening principles, outcome data collection, and the cohort studies included in the sub-group analysis
O
their review and suggestions
P
8050 patients
I/C
Cyclosporine + methotrexate + Anti-T cell globulin (ATG), tacrolimus + methotrexate + ATG, tacrolimus + bortezomib + sirolimus, cyclosporine + marrow mesenchymal stem cells (MMSCs), corticosteroids alone
O
proportion of patients who respond to therapies